Alcyone Lifesciences
Ayer
About Alcyone Lifesciences
Alcyone Lifesciences develops a platform of technology that optimizes molecular therapy for the brain. It addresses the unmet needs in the treatment of chronic neuropathological conditions. For many neurologic conditions, there are identified molecular targets, but the blood-brain barrier prevents drugs from addressing those targets from reaching diseased brain regions in a controlled and targeted manner. In addition, there is a fundamental need for control and precision in molecular therapy to the CNS. The company is transforming disease-modifying therapies for rare and orphan disorders through Advanced Precision Delivery Platforms.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $15.6M
- Last round: Series Unknown (Jan 2018)
- Website: alcyonels.com
- Phone: (978)709-1946
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/alcyone-lifesciences-140072 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.